Taking a GLP-1 receptor agonist was associated with a lower risk for cirrhosis and related complications in patients with ...

After insurance for New York City employees began covering GLP-1 weight-loss injectables, more than 1,000 city workers and ...

Study of those who started taking blockbuster weight loss drugs in 2021 suggests patients need support services, not just the ...

When food enters the digestive system, specialized cells in the small intestine release GLP-1, initiating a cascade of ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter.

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) is pioneering a new wave of medical treatment for diabetes and obesity ...

Contrary to concerns, GLP-1RA medications don’t appear to elevate AKI risk in patients undergoing cancer treatment.

Recent updates from the American Stroke Association reveal groundbreaking strategies for preventing strokes, which affect ...

New stroke prevention guidelines highlight key interventions for cardiovascular health, as well as emerging evidence on ...

The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...

Renowned plant-based physician Dr. Michael Greger has released a new book on the risks, benefits, and alternatives to Ozempic ...